Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Moghal

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

MTE01.02 Lung Patient Derived Xenograft and Organoid

Journal of Thoracic Oncology

English

Related publications

How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?

Journal of Thoracic Oncology

English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma

English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology

Oncology

2012

English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology

Oncology

2012

English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy

Oncology

Pharmacology

2015

English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Moghal

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

MTE01.02 Lung Patient Derived Xenograft and Organoid

Related publications

How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients